Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Biotransformation of [14C]GB491 (Lerociclib) in Healthy Chinese Males
NCT05860582Phase 1Completed
- Sponsor
- Genor Biopharma
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lerociclib in breast cancer and non-small cell lung cancer (NSCLC), sponsored by Genor Biopharma. Primary endpoints: Total radioactivity in plasma PK, Total radioactivity in urine and fecal samples and 1 more. Started Sep 2022; status: completed.
02
Drugs
lerociclib
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05860582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05860582.